Mandate

Vinge advises Oncopeptides in connection with a directed share issue

March 23, 2018

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 314 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by ABG Sundal Collier AB, Carnegie Investment Bank AB (publ), DNB Markets, a part of DNB Bank ASA, and Jefferies International Limited.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Johan Winnerblad, Sofie Bjärtun and Hampus Olsson.

Related

Vinge advises Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood

Vinge has advised Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood Grupp OÜ (“Combiwood”).
May 22, 2025

Vinge has advised the FEA Group, which includes Freys Hyrverk and Stockholm Limousine Service, in connection with its merger with Inclusion Services International

The merger strengthens the new FEA Group’s capacity and service offering, which includes everything from comprehensive travel planning and hotel bookings to security-classified passenger transport and risk assessments. According to management, the newly formed group will have a unique position in the Swedish market with the opportunity to introduce new transport and security solutions that are currently unmatched in the country.
May 21, 2025

Vinge advises EHF Invest on its public offer for Real Fastigheter

EHF Invest AB has made a public offer for all shares in Real Fastigheter AB (publ).
May 21, 2025